WSJ's editorial page puts the blame over Exondys 51 controversy on insurers, regulators and reporters
Throughout its quest to get an FDA approval for Exondys 51, one of Sarepta’s most influential backers has been the editorial page at the Wall Street Journal, which loudly and angrily insisted on an accelerated OK. And now that it helped win that fight, the newspaper’s editorial group — as distinct from its reporters — has turned its sights on insurers who are restricting coverage as well as the reporters and regulators they find responsible for the payer backlash.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
